{
  "id": "6024a4111cb411341a0000a2",
  "type": "factoid",
  "question": "Which molecule is targeted by Teprotumumab?",
  "ideal_answer": "Teprotumumab is a human monoclonal antibody that targets IGF-1R. It can be used for treatment of thyroid eye disease.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30575804",
    "http://www.ncbi.nlm.nih.gov/pubmed/29273685",
    "http://www.ncbi.nlm.nih.gov/pubmed/31377284",
    "http://www.ncbi.nlm.nih.gov/pubmed/31813786",
    "http://www.ncbi.nlm.nih.gov/pubmed/30385883",
    "http://www.ncbi.nlm.nih.gov/pubmed/25105999",
    "http://www.ncbi.nlm.nih.gov/pubmed/26087256",
    "http://www.ncbi.nlm.nih.gov/pubmed/33221815",
    "http://www.ncbi.nlm.nih.gov/pubmed/32088116",
    "http://www.ncbi.nlm.nih.gov/pubmed/32040069",
    "http://www.ncbi.nlm.nih.gov/pubmed/32059832",
    "http://www.ncbi.nlm.nih.gov/pubmed/32157641",
    "http://www.ncbi.nlm.nih.gov/pubmed/31814726",
    "http://www.ncbi.nlm.nih.gov/pubmed/30215690",
    "http://www.ncbi.nlm.nih.gov/pubmed/32429706",
    "http://www.ncbi.nlm.nih.gov/pubmed/26361263",
    "http://www.ncbi.nlm.nih.gov/pubmed/32707005",
    "http://www.ncbi.nlm.nih.gov/pubmed/31971679",
    "http://www.ncbi.nlm.nih.gov/pubmed/31356255",
    "http://www.ncbi.nlm.nih.gov/pubmed/24878056",
    "http://www.ncbi.nlm.nih.gov/pubmed/28467880",
    "http://www.ncbi.nlm.nih.gov/pubmed/29744034",
    "http://www.ncbi.nlm.nih.gov/pubmed/32795835",
    "http://www.ncbi.nlm.nih.gov/pubmed/33237667"
  ],
  "snippets": [
    {
      "text": "Teprotumumab (a human monoclonal anti-IGF-1R blocking antibody) has been investigated in a trial, showing it was very effective in GO patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31813786",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS: In a randomized, double-masked, placebo-controlled, phase 3 multicenter trial, we assigned patients with active thyroid eye disease in a 1:1 ratio to receive intravenous infusions of the IGF-IR inhibitor teprotumumab (10 mg per kilogram of body weight for the first infusion and 20 mg per kilogram for subsequent infusions) or placebo once every 3 weeks for 21 weeks; the last trial visit for this analysis was at week 24. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31971679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, an IGF-IR inhibitor, teprotumumab, has emerged from 2 clinical trials as a promising treatment for active, moderate to severe TAO. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32040069",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, teprotumumab (a human monoclonal anti-IGF-1R blocking antibody) showed to be very effective in GO patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32059832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RT OPINION: Teprotumumab is a human monoclonal antibody targeting insulin-like growth factor-I receptor. Cli",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32707005",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab is a human insulin-like growth factor-I receptor monoclonal inhibitor antibody which indicated for treating thyroid eye disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32707005",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "cent completion of phase 2 and 3 randomized, placebo-controlled trials demonstrate the efficacy and safety of teprotumumab, a fully human monoclonal IGF-1R antagonist antibody, in patients with moderate-to-severe, active TED. Both ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31377284",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent advances in the understanding of the molecular basis of TED have facilitated the development of targeted molecular therapies such as teprotumumab, an insulin-like growth factor-1 receptor inhibiting monoclonal antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31814726",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he most promising results are observed with small thyroid stimulating hormone receptor molecules interacting with the receptor on thyrocytes and fibroblasts and with the anti-IGF-1 receptor antibody teprotumumab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25105999",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TSH-Mediated TNF\u03b1 Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26087256",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "These observations served as the rationale for implementing a recently completed therapeutic trial of teprotumumab, a monoclonal inhibitory antibody targeting IGF-IR in TAO.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30215690",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ting downstream of IGF1-R, sirolimus may offer a cost-effective alternative to teprotumumab therapy. Clin",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33237667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, teprotumumab (a human monoclonal anti-IGF-1R blocking antibody) showed to be very effective in GO patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32059832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Teprotumumab (TMB) is a human monoclonal IGF-1R blocking antibody currently in clinical trial for GO and inhibits TSHR-mediated actions in FCs",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26087256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab (teprotumumab-trbw; TEPEZZA\u2122 - Horizon Therapeutics) is a monoclonal antibody insulin-like growth factor-I receptor (IGF-IR) antagonist developed for the treatment of thyroid eye disease (Graves ophthalmopathy/orbitopathy, thyroid-associated ophthalmopathy).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32157641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Most promising results are obtained by interacting with the PIK3/mTORC1 signaling cascades for adipogenesis and the anti-IGF-1R with the monoclonal antibody teprotumumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26361263",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Teprotumumab (RV 001, R1507) is a human monoclonal anti-IGF-1R blocking antibody currently undergoing a phase 2 clinical trial in patients with active TAO",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24878056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A recently completed therapeutic trial of teprotumumab, a human IGF1R inhibiting antibody, in patients with moderate to severe, active TAO, indicates the potential effectiveness and safety of the drug.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29273685",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab is a monoclonal antibody directed against the IGF-1R that was FDA-approved in 2020 for the treatment of Graves' orbitopathy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32795835",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ecent completion of phase 2 and 3 randomized, placebo-controlled trials demonstrate the efficacy and safety of teprotumumab, a fully human monoclonal IGF-1R antagonist antibody, in patients with moderate-to-severe, active TED. Both",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31377284",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24878056",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "GN: Fibrocytes were treated without or with teprotumumab in combination with IGF-1 or TSH.MAI",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24878056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Fibrocyte display of IGF-1R and TSHR was reduced with teprotumumab, as were IGF-1- and TSH-dependent phosphorylated Akt levels. TSH in",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24878056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "S: Teprotumumab attenuates the actions of both IGF-1 and TSH in fibrocytes. Specific",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24878056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab, a blocking antibody to the insulin like growth factor 1 receptor (IGF-1R) has been shown to significantly reduce proptosis in recent phase 2 and 3 trials in patients with inflammatory thyroid eye disease (TED).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33221815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " findings demonstrate for the first time, that teprotumumab, a blocking antibody to the IGF-1R reduces proptosis in a series of patients with non-inflammatory TED. Ov",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33221815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab, a monoclonal IGF-1R antagonist, has demonstrated previously in a 24 week, randomized, controlled trial to produce significant changes in composite outcomes of proptosis and clinical activity score as compared with placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30575804",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30575804",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ar condition. Teprotumumab is a human insulin-like growth factor-I receptor monoclonal inhibitor antibody which indicated for treating thyroid eye disease.AREAS COVERED: The authors performed a systematic review of the literature using the PubMed database, and the following keywords were used: 'teprotumumab,' 'thyroid eye disease,' and 'insulin-li",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32707005",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "y concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy.METHODS: We conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-s",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467880",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In addition, targeted biologic therapies have shown promise, including teprotumumab (anti-IGFR) which appears to substantially reduce proptosis, rituximab (anti-CD20) which reduces inflammation and tocilizumab (anti-IL-6) which potentially benefits both of these parameters.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31356255",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teprotumumab (Tepezza) is a human monoclonal antibody against the insulin-like growth factor type I receptor (IGF-IR), recently evaluated in two clinical trials for active moderate-to-severe TAO that was recently approved by the United States Food and Drug Administration (FDA) for use in TAO.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32429706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Despite these challenges, several agents, most developed for treatment of other diseases, have found their way into consideration for use in active TAO through repurposing. Among these, teprotumumab is a fully human inhibitory monoclonal antibody against the insulin-like growth factor I receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32088116",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results from a very recently published clinical trial assessing the safety and efficacy of teprotumumab, an inhibitory human anti-IGF-IR monoclonal antibody, in active, moderate to severe TAO are extremely encouraging.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29744034",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "IGF-1R"
}